Gieschke R, Schmid-Burgk W, Amrein R
Department of Clinical Research, F. Hoffmann-La Roche & Co., Ltd., Basle, Switzerland.
J Neural Transm Suppl. 1988;26:97-104.
In a double-blind placebo-controlled cross-over study in 8 healthy volunteers possible interactions between moclobemide and tyramine were studied. Eight volunteers received either moclobemide or placebo for a period of 6 days and received tyramine on day 5 and day 6 of each treatment period. Moclobemide was given in a daily dose of 450 mg to be taken in three divided doses at the end of the meals. Tyramine was administered in the form of an artificially tyramine enriched cheese (camembert) together with a meal at noon. The total tyramine doses administered were 50 mg on day 5 and 100 mg on day 6 of each treatment period. Comparisons of blood pressure and heart rate changes after tyramine ingestion between moclobemide and placebo conditions did not indicate any relevant moclobemide-tyramine interaction. It is concluded that tyramine in quantities of up to 100 mg does not lead to clinically relevant blood pressure reactions in moclobemide-treated subjects, if moclobemide is taken at the end of the meal.
在一项针对8名健康志愿者的双盲安慰剂对照交叉研究中，研究了吗氯贝胺与酪胺之间可能的相互作用。8名志愿者在每个治疗期接受吗氯贝胺或安慰剂治疗6天，并在每个治疗期的第5天和第6天接受酪胺。吗氯贝胺的日剂量为450mg，分三次在餐末服用。酪胺以人工富含酪胺的奶酪（卡芒贝尔奶酪）的形式与午餐一起服用。每个治疗期第5天的酪胺总剂量为50mg，第6天为100mg。吗氯贝胺和安慰剂条件下摄入酪胺后血压和心率变化的比较未显示任何相关的吗氯贝胺 - 酪胺相互作用。得出的结论是，如果在餐末服用吗氯贝胺，高达100mg的酪胺不会在接受吗氯贝胺治疗的受试者中引起临床相关的血压反应。
